Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | The issue of drug cost: transparent pricing & acceptable profit margins

Anton Hagenbeek • 9 Jun 2016
EHA 2016
General

Anton Hagenbeek, MD, PhD from the University of Amsterdam, Amsterdam, Netherlands talks about the issue of drug costs in oncology. Drug combinations are effective but particulalry costly according to Prof. Hagenbeek. He argues that there is an urgent need to talk to the biotech companies producing the drugs and to agree on transparent pricing of these drugs and socially acceptable profit margins.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Anton Hagenbeek

12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
23:19
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
Anton Hagenbeek et al. • 9 Apr 2015
iwNHL 2015 roundtable: The changing treatment landscape for non-Hodgkin lymphoma
16:39
iwNHL 2015 roundtable: The changing treatment landscape for non-Hodgkin lymphoma
Andrew Zelenetz et al. • 3 Oct 2015
Immuno-oncology opportunities for the treatment of lymphoma
2:56
Immuno-oncology opportunities for the treatment of lymphoma
Anton Hagenbeek • 4 Dec 2015
Brentuximib vedotin therapy for Hodgkin lymphoma
2:18
Brentuximib vedotin therapy for Hodgkin lymphoma
Anton Hagenbeek • 9 Dec 2014

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals